REGULATORY
Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
Pharma trade groups of Japan, the US, and Europe all came in alignment with each other to call for revisiting the current drug price revision mechanism at an industry hearing on September 22, proposing discussions on “official margins” for wholesalers…
To read the full story
Related Article
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





